Blood
& Urine Drug Testing for Cannabinoids
Matthew
J Atha BSc MSc LLB
Independent
Drug Monitoring Unit Updated 5 December 2000
Click
Here to download as a pdf
1. General
1.1
In the light of the serious consequences for the individual,
and liabilities which can be incurred in the event of
a positive or incorrect test result, Simpson et al[1]
discussed the need for established procedures covering
storage, chain of custody, confirmation of results and
appropriate legal standards for "library" matching
of spectra from unknown substances (e.g. designer drugs)
requiring identification.
1.2
Most blood and urine tests for the presence of cannabinoids
differ from alcohol test results as these measure inactive
metabolites of cannabis, and not the active drug itself.
Alcohol produces clear dose-related impairment as measured
by breath, blood or urine tests. The presence of cannabinoids
in urine merely signifies that the person had used or
been exposed to cannabis at some point prior to the test[2].
2.
Cannabis Pharmacokinetics
2.1
Pharmacokinetics is the study of the time course of how
drugs are distributed in the body, how long the effects
last and how such effects relate to drug tests.
2.2
The major problem with measurement of metabolites is the
very long detection times, owing the the rapid deposition
of cannabinoids in inert fatty tissue following administration.
Johannson et al[3]
reported that total amount of THC metabolites and the
levels of delta THC-acid could be followed up to 25 days
after abstinence using EMIT cannabinoid assay and HPLC.
2.3
The residual level of THC in the bloodstream occurs when
THC is released from the adipose (fatty) tissues, where
it is deposited shortly after smoking. THC is also converted
to its inert acid form within minutes of ingestion[4].
The half-life of THC in fatty tissue is approximately
8 days[5][6]. There is little
evidence that clearance rates for THC differ significantly
between naive and experienced cannabis users.
2.4
The distribution of THC in body tissues is shown in fig
1 below. Plasma levels drop dramatically following cessation
of use, with increased absorption in the brain and high
perfusion tissues, but after 1 hour residual levels fall
much more gradually. Levels in body fat increase over
a period of hours or days, and slowly release metabolites
into the bloodstream thereafter. The slow clearance rate
from body fat is the main reason why cannabinoids can
be detected in blood or urine for many days or weeks following
cessation of use.
Fig
1 - Distribution of THC in the Body (Kreutz & Axelrod
(1973)[7]

2.5
Harder & Rietbrock[8]
noted the effects on plasma levels and intoxication produced
by smoking different strengths of "joint" at
different intervals, finding that the effect of a strong
(9mg) reefer would last around 45min, or if smoked continuously
a recovery within 100 minutes, with a continuous high
if smoked hourly with a recovery after 150 minutes. Weak
(3mg) and hemp (1mg) reefers produced lower levels of
intoxication and more rapid recovery times.
2.6
Chesher[9]
summarised that.the inactive metabolite THC acid, formed
in the liver from metabolism of THC, appears after THC
in blood, and if present when the a subsequent dose is
smoked, higher concentrations would ensue. Unmetabolised
THC may be stored, and gradually released, from body fat
for up to 28 days in chronic users. He commented: "analytical
data that provides a value only for the metabolite can
only be validly interpreted as indicating recent consumption
of cannabis ... a matter of hours or days. For this reason
quantitative determination of only the metabolite is of
no value to determine possible impairment."
2.7
McBurney et al [10]describe a study of plasma concentrations
of THC in users where one subject was rejected as having
a concentration of 37ng/ml prior to the test. It is not
stated when the subject had last smoked marijuana. Perez-Reyes
et al[11] tested concentrations in experienced
marijuana smokers who had refrained for 6 days prior to
the experiment. Two cigarettes, with an average of 882mg
cannabis at 1% THC (8.82mg THC), were smoked two hours
apart, blood samples being taken every 5 minutes for the
first 20 minutes after smoking, and at 10 minute intervals
thereafter. The first cigarette produced a level of 70ng/ml
at 10 minutes roughly 17ng/ml at 20 min, and roughly 3ng/ml
at 2 hours. The second produced respective levels of 90,
17 and 5ng/ml at similar intervals after smoking. There
is a rapid rise in THC concentration during smoking, and
then an equally rapid fall which levels off at roughly
30 min post-smoking and falls gradually thereafter.
2.8
Sticht & Kaferstein[12]
estimated that the blood THC concentrations produced in
a 70kg person smoking 15mg THC would peak at 7-8 minutes,
after 30 minutes between 14-42ng/ml, and at 60 minutes
between 7.5-14ng/ml. Rosencranz[13]
reported that blood levels of THC peak at 5 minutes, with
a distribution half-life of 30 minutes, and elimination
half-life of 18-36 hours. For THC-acid, levels peaked
at 20 minutes, with distribution and elimination half-lives
of 15-30 minutes and 24-72 hours respectively.
2.9
Agurell et al[14]
studied THC levels in one "heavy marijuana user.
His plasma THC was measured each day for four days before
and one hour after smoking one cigarette laced with 10mg
radioactively labelled THC, and for 8 days after ceasing
all use. Prior to the experiment his plasma THC was roughly
20ng/ml. The levels of labelled and unlabelled THC both
rose after smoking each cigarette, indicating that existing
THC may be displaced from the fatty tissues as fresh THC
is absorbed. The pre-smoking unlabelled (i.e. residual)
THC level fell steadily over the period of the experiment
(20ng to 9ng to 8ng to 2ng/ml on successive days), still
exceeding ten-fold the labelled (i.e. fresh) THC concentration.
After 8 days abstinence the levels were 1ng/ml unlabelled,
and 0.1ng/ml labelled. The decline during the first period
of the experiment, when the subject was smoking 10mg THC
per day, indicates that his normal consumption may have
exceeded this level, possibly by ten-fold or more, i.e.
100mg THC per day.
2.10
Cone & Huestis[15]
postulated a model for predicting the time of marijuana
exposure from relative plasma concentrations of THC and
THC-carboxy acid metabolite (THCCOOH). These models were
based on data from a controlled clinical study of marijuana
smoking. Such models allow prediction of the elapsed time
since marijuana use based on analysis for cannabinoids
from a single plasma sample and provide accompanying 95%
confidence intervals around the prediction. They noted
that concentration estimates in the range of 7-29 ng/ml
for amount of THC in blood is necessary for production
of 50% of the maximal subjective high effect. Their models
were based on either THC concentration, or on the ratio
of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH)
to THC in plasma[16],
noting that their predicted times of exposure were generally
accurate but tended to overestimate time immediately after
smoking and tended to underestimate later times..
2.11
Cami et al[17]
studied the effects of expectancy on intoxication, noting
a tendency toward more marked subjective effects in subjects
who expected and received the drug, and that positive
expectancy induced powerful subjective effects in the
absence of active THC.
3.
Metabolite or active drug?
3.1
It has been postulated, on the basis of experimental studies,
that levels of 11-hydroxy THC (a psychoactive metabolite)
in excess of 20ng/ml may be indicative of recent use[18],
however this study used single doses, or a short series
of doses, of THC (150µg/kg) on volunteers, and would not
measure residual cannabinoid levels in longer-term users.
There was a substantial variation in clearance rates,
with several subjects showing total cannabinoids in urine
samples (measured by EMIT) to be higher 18-22 hours after
ingestion than 0-6 hours after consumption.
3.2
Reeve et al[19]
compared plasma THC levels with performance on the roadside
sobriety test, finding that failures were associated with
levels over 25-30ng/ml. Sticht & Kaferstein[20]
estimated that the blood THC concentrations produced in
a 70kg person smoking 15mg THC would peak at 7-8 minutes,
after 30 minutes between 14-42ng/ml, and at 60 minutes
between 7.5-14ng/ml.
3.3
McBay[21]
compared THC and THC-COOH levels in a study involving
smoked marijuana cigarettes. THC-acid levels increased
steadily following smoking, but were still detectable
long after intoxication would have ceased. Plasma THC
levels declined rapidly following cessation of smoking,
but were almost all still over 10ng/ml one hour later,
and in the range of 1ng to 10ng/ml 2-4 hours after cessation
of smoking.
3.4
Although there are many papers reporting plasma THC levels,
there are no papers which unequivocally relate plasma
THC levels with overall consumption. Most have been experimental
studies matching short-term THC levels with perceived
psychotropic effects.
4.
False Positives and Passive Smoking
4.1
Screening tests need to be confirmed by GCMS analysis,
as positives may be obtained by consumption on non-psychoactive
substances such as hemp-seed bars[22],
or milk from cattle grazing on wild cannabis[23] (which could include hemp silage).
4.2
Positive tests for cannabinoids in urine may also occur
as a result of passive smoking, with cannabinoid (THC-acid)
levels of over 20ng/ml detectable in one case 4 days after
passive exposure[24]. It was concluded that presence of cannabinoids
in urine or blood is not unequivocal proof of active cannabis
smoking. Giardino[25]
reported that poor air quality could lead to THC-acid
positives (>15ng/ml) arising from passive inhalation
of cannabis smoke. Magerl et al[26] found THC-acid levels of up to 30-50ng/ml from
passive-exposed subjects, and recommended a threshold
of 65ng/ml to differentiate between active and passive
smoking of cannabis.
4.3
Mason et al[27]
produced plasma THC levels of 2.0-2.2ng/ml in passive
smokers in a confined space, whereas plasma THC was not
detected in a study by Law et al[28]
in a separate closed-space study where the smokers developed
THC of 7.5ng/ml.
4.4
In a review of passive inhalation studies, Hayden[29] reported that most studies support the proposition
that passive inhalation should be seriously considered
as a possible explanation for a positive urine test for
marijuana, although he noted that passive inhalation does
not have a major effect outside the laboratory.
5
Determining Current Use - saliva testing?
5.1
Valentine & Psaltis[30]
suggested use of fluorometic assay for detection of cannabinol
in human saliva as a correlate of use, and also suggested
detection mechanisms for breath[31]
Kircher et al[32] describes the use of tandem
immunoaffinity chromatography and HPLC for determination
of D9 THC concentration in deproteinised human
saliva.
5.2
Menkes et al[33]
studied salivary THC levels, subjective intoxication and
heart rate among 13 experienced volunteers abstinent for
one week before the test. Baseline THC levels of up to
3.4ng/ml (nanograms per millilitre) were recorded (mean
0.36ng/ml). After smoking a single cigarette containing
11mg THC, salivary THC levels substantially exceeded 100ng/ml
for the first hour after smoking, with levels over 10ng/ml
persisting for up to 4 hours (fig 2).
5.3
Self-reported intoxication and heart rate were both substantially
elevated for over 1hour, heart rate was close to baseline
by 80min, and low levels of intoxication reported up to
3 hours after smoking. Salivary THC levels over 100ng/ml
were associated with clear intoxication, and levels over
50ng/ml with mild intoxication.
Fig
2. Salivary THC and subjective intoxication (Menkes et
al)

5.4
Four British police forces tested sweat or saliva testing
devices in early 1998, however in December 1998 the DETR
stated that "
the
operating mechanisms in both devices sometimes failed
or proved unreliable, and the notation by police of positive
or negative readings from the devices simply cannot be
regarded as meaningful. We cannot therefore use the data
in any way that could be construed as indicative of drug
use among drivers and it would be irresponsible if we
were to attempt to do so" and conceded that "the
incidence of drugs in road accident casualties...does
not give us any help with accident causation"[34]
6
Significance of test results - Policy & Practice
6.1
Most urine tests only detect an inactive metabolite -
THC carboxylic acid. The results for cannabinoid metabolites
in urine are of no significance whatsoever in determining
intoxication or performance impairment, as the THC-acid
is not an active compound, and can persist for many weeks
after chronic use. Presence of active drug (i.e. THC -
delta-9-tetrahydrocannabinol), or active metabolite 11-hydroxy
THC - present in the period shortly following smoking
of cannabis) would indicate recent use capable of causing
intoxication or impairment.
6.2
A positive sample could easily be caused by passive smoking,
or ingestion of non-psychoactive cannabis products (e.g.
hemp seed bars). Such a sample could also have been produced
days or weeks after taking the drug, long after any cannabis
taken would have ceased to have any effect.
6.3
In many labs the cutoff threshold for "cannabis"
- a misleading term when metabolite is measured - is extremely
low (15ng/ml), in comparison to other drugs. For instance
amphetamine thresholds are commonly 1000ng/ml, or 1 microgram
per millilitre, representing a relatively high dosage
for the average individual, such as might be produced
shortly after taking a gram of street "speed".
6.4
I note the cut off threshold used for urine testing by
Home Office researchers[35]
is 50ng/ml, when using the EMIT (immunoassay) technique.
Magerl et al[36] recommended a threshold of 65ng/ml
to differentiate between active and passive smoking.
6.5
I would consider the cut-off threshold currently in widespread
use by drug testing laboratories to be unreasonably low,
and highly susceptible to false-positive results. Testing
for the THC-acid metabolite has no relevance to considerations
of impairment or intoxication "on the job".
References
[1] Simpson D, Braithwaite RA, Jarvie
DR, Stewart MJ, Walker S, Watson IW, Widdop B (1997)
Screening for drugs of abuse (II): Cannabinoids, lysergic
acid diethylamide, buprenorphine, methadone, barbiturates,
benzodiazepines and other drugs. Ann Clin Biochem 34
( Pt 5):460-510
[2] Blanke et al (1985) Journal
of the American Medical Association 254(18) p2618
[3] Johansson E, Halldin MM (1989) Urinary
excretion half-life of delta 1-tetrahydrocannabinol-7-oic
acid in heavy marijuana users after smoking. J Anal
Toxicol 13(4):218-23
[4] Cone EJ & Huestis MA (1993)
Relating Blood Concentrations of Tetrahydrocannabinol
and Metabolites to Pharmacological Effects and Time
of Marijuana Usage. Therapeutic Drug Monitoring
15 pp527-532
[5] Johansson E, Sjovall J, Noren
K. Agurell S, Hollister LE & Halldin MM (1987) Analysis
of D1-tetrahydrocannabinol (1-THC)
in human plasma and fat after smoking. In Chesher G,
Consroe P & Musty R (Eds) Marijuana: An International
Research Report Proceedings of the Melbourne Symposium
on Cannabis 2-4 September 1987. Canberra: Australian
Government Publishing Service.
[6] Nahas GG & Latour C (1992)
The Human Toxicity of Marijuana. The Medical Journal
of Australia 166 (8-5-92) pp495-497
[7] Kreutz DS & Axelrod J (1973)
Delta-9-tetrahydrocannabinol: localisation in body fat.
Science 179 pp391-392
[8] Harder S, Rietbrock S (1997) Concentration-effect
relationship of delta-9-tetrahydrocannabiol and prediction
of psychotropic effects after smoking marijuana. Int
J Clin Pharmacol Ther 35(4):155-9
[9] Chesher GB (1995) Cannabis
and Road Safety: an outline of the research studies
to examine the effects of cannabis on driving skills
and on actual driving performance. Dept of Pharmacology,
University of Sydney/National Drug &Alcohol Research
Centre/University of New South Wales.
[10] McBurney LJ, Bobbie BA, &
Sepp LA (1986) GC/MS and EMIT Analyses for D9-Tetrahydrocannabinol
metabolites in plasma and urine of human subjects. Journal
of Analytical Toxicology 10 (Mar/April 1986) pp56-64
[11] Perez-Reyes M, Owens SM &
diGuiseppi S (1981) The Clinial Pharmacology and Dynamics
of Marijuana Cigarette Smoking. Journal of Clinical
Pharmacology. 21 pp201s-207s
[12] Sticht G & Kaferstein
H (1995) Pharmacokinetic evaluation of published studies
on controlled smoking of marijuana. In Kloeden N &
McLean AJ (Eds) Alcohol, Drugs & Traffic Safety.
Vol 1, pp 397-402. Adelaide, NHMRC Road Accident Research
Unit.
[13] Rozenkranz H (1983) Cannabis,
marijuana & cannabinoid toxicology manifestations
in man and animals. In Fehr KO & Kalant H (eds)
Cannabis and Health Hazards. Toronto: Addiction Research
Foundation.
[14] Agurell S, Gillespie H, Halldin
M,Hollister LE, Johansson J, Lindgren JE, Ohlsson A,
Szirmal M & Widman M (1984) A review of recent studies
on the pharmacokinetics and metabolism of D-1-tetrahydrocannabinol,
cannabidiol and Cannabinol in man. Ch in Harvey D, Paton
W & Nahas GG(Eds) Marijuana 84 - Proceedings
of the Oxford Symposium on Cannabis. Oxford, Washington
DC: IRL Press
[15] Cone EJ, Huestis MA (1993) Relating blood
concentrations of tetrahydrocannabinol and metabolites
to pharmacologic effects and time of marijuana usage.
Ther Drug Monit 15(6):527-32
[16] Huestis MA, Henningfield JE, Cone EJ
(1992) Blood cannabinoids. II. Models for the prediction
of time of marijuana exposure from plasma concentrations
of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta
9-tetrahydrocannabinol. J Anal Toxicol 16(5):283-90
[17] Cami J, Guerra D, Ugena B, Segura J,
de la Torre R (1991) Effect of subject expectancy on
the THC intoxication and disposition from smoked hashish
cigarettes. Pharmacol Biochem Behav 40(1):115-9
[18] McBurney LJ, Bobbie BA, &
Sepp LA (1986) GC/MS and EMIT Analyses for D9-Tetrahydrocannabinol
metabolites in plasma and urine of human subjects. Journal
of Analytical Toxicology 10 (Mar/April 1986) pp56-64
[19] Reeve VC, Grant JD, Robertson
W, Gillespie HK & Hollister LE (1983) Plasma concentrations
of ∂-9 tetrahydrocannabinol and impaired motor
function. Drug & Alcohol Dependence 11 pp167-175
[20] Sticht G & Kaferstein
H (1995) Pharmacokinetic evaluation of published studies
on controlled smoking of marijuana. In Kloeden N &
McLean AJ (Eds) Alcohol, Drugs & Traffic Safety.
Vol 1, pp 397-402. Adelaide, NHMRC Road Accident Research
Unit.
[21] McBay AJ (1988) Interpretation of blood
and urine cannabinoid concentrations. J Forensic Sci
33(4):875-83
[22] Fortner N, Fogerson R, Lindman D, Iversen
T, Armbruster D (1997) Marijuana-positive urine test
results from consumption of hemp seeds in food products.
J Anal Toxicol 21(6):476-81
[23] Ahmad GR, Ahmad N (1990) Passive
consumption of marijuana through milk: a low level chronic
exposure to delta-9-tetrahydrocannabinol (THC). J Toxicol
Clin Toxicol 28(2):255-60
[24] Morland J, Bugge A, Skuterund
B, Steen A, Wethe GH & Kjeldsen T (1985) Cannabinoids
in blood and urine after passive inhalation of marijuana
smoke. Journal of Forensic Sciences, 30(4) pp997-1002
[25] Giardino NJ (1997) An indoor air quality-pharmacokinetic
simulation of passive inhalation of marijuana smoke
and the resultant buildup of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic
acid in urine. J Forensic Sci 42(2):323-5
[26] Magerl H, Wiegand C, Schulz
E (1987) [Cannabinoid intake by passive smoking]. [Article
in German] Arch Kriminol 179(1-2):31-7
[27] Mason AP, Perez-Reyes M, McBay
AJ (1983) Cannabinoid concentrations in plasma after
passive inhalation of cannabis smoke. J Anal Toxicol
7 172-174
[28] Law B, Mason PA, Moffat AC
(1984) Passive inhalation of cannabis smoke. J Pharm
Pharmacol 36 pp578-581
[29] Hayden JW (1991) Passive inhalation of
marijuana smoke: a critical review. J Subst Abuse 1991;3(1):85-90
[30] Valentine JL & Psaltis
P (1979) Detection of Marijuana Use in Human Saliva
using a fluorometric assay based on cannabinol decomposition.
Analytical Letters 12 (B8) pp855-866
[31] Valentine JL Bryant PJ, Gutshall
PL, Owen HMG & Niu HG (1979) Detection of ∆9-tetrahudrocannabinol
in in Human breath following marijuana smoking. Analytical
Letters 12 (B8) pp867-880
[32] Kircher V, Parlar H (1996)
Determination of delta 9-tetrahydrocannabinol from human
saliva by tandem immunoaffinity chromatography--high-performance
liquid chromatography. J Chromatogr B Biomed Appl 677(2):245-55
[33] Menkes DB, Howerd RC, Spears
GFS & Cairns ER (1991) Salivary THC following cannabis
smoking correlates with subjective intoxication and
heart rate. Psychopharmacology 103 pp277-279
[34] Lord Whitty - Minister for
Roads (1998) DETR letter to Paul Flynn MP, ref J/W/PSO/13179/98
[35] Bennett T (2000) Drugs &
Crime: The results of the second development stage of
the NEW-ADAM programme. Home Office Research Study p205.
London: Home Office p11
[36] Magerl H, Wiegand C, Schulz
E (1987) [Cannabinoid intake by passive smoking]. [Article
in German] Arch Kriminol 179(1-2):31-